Growth Outcomes After 48 Weeks of Dolutegravir in Children and Adolescents With HIV-1 in IMPAACT P1093 and IMPAACT 2019
Journal of the Pediatric Infectious Diseases Society · 2026
DOI: 10.1093/jpids/piag088 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, 2026. Verfasst von Michael McKenna und 11 weiteren Autor:innen. Beteiligte Einrichtung: GSK, London, United Kingdom. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, HIV Infections, HIV Integrase Inhibitors, HIV-1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network, NICHD NIH HHS, NIAID NIH HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
We evaluated growth outcomes in children and adolescents with HIV-1 initiating or switching to dolutegravir-based antiretroviral therapy (ART) in the single-arm International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network studies P1093 and IMPAACT 2019.
Methods
We performed descriptive post hoc analyses of body mass index–for-age (BAZ), weight-for-age (WAZ), and length/height-for-age z scores (L/HAZ) for each trial through Week 48. Changes in BAZ were assessed using a mixed model for repeated measures.
Results
We included data from 181 and 57 participants from P1093 and IMPAACT 2019, respectively (10% [23/238] were adolescents). Baseline mean BAZ was −0.1 in P1093 and −0.7 in IMPAACT 2019. At Week 48, adjusted mean BAZ increased significantly in P1093 (0.3; 95% CI, 0.03, 0.49; P < .05) and non-significantly in IMPAACT 2019 (0.3; 95% CI, −0.03, 0.58; P = .074). Mean BAZ was in the normal range at Week 48 in both trials. Marked increases in BAZ were observed among subgroups with baseline BAZ <−2. By Week 48, 65% (117/181) of participants in P1093 and 74% (42/57) in IMPAACT 2019 remained in the same BAZ category. Improvements from severe or moderate malnutrition/thinness to normal weight occurred in 6% (10/181) and 7% (4/57) of participants in P1093 and IMPAACT 2019, respectively, while increases to overweight or obesity were observed in 9% (16/181) and 5% (3/57). Small changes were observed in overall mean WAZ and L/HAZ through Week 48 in both trials.
Conclusion
Small overall increases in BAZ were observed over 1 year among pediatric participants on dolutegravir-based ART, with most participants remaining in their baseline BAZ category. Clinical trial information ClinicalTrials.gov, NCT01302847 and NCT03760458.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GSK, London, United Kingdom.
- ViiV Healthcare, Durham, NC, United States.
- ViiV Healthcare, London, United Kingdom.
- GSK, Collegeville, PA, United States.
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
- Division of Pediatric Infectious Diseases and Global Health, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, United States.
ORCID-Profile: Lauren Ziemba, Andrew Wiznia
Förderung
- International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network
- NICHD NIH HHS
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- NIH HHS
- NIMH NIH HHS
- ViiV Healthcare
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
Zitieren
APA
McKenna, M., Lulic, Z., Buchanan, A. M., Brothers, C., Tan, L. K., Wang, M., Brummel, S., Ziemba, L., Ruel, T., Flynn, P. M., Rabie, H., & Wiznia, A. (2026). Growth Outcomes After 48 Weeks of Dolutegravir in Children and Adolescents With HIV-1 in IMPAACT P1093 and IMPAACT 2019. Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piag088
Vancouver
McKenna M, Lulic Z, Buchanan AM, Brothers C, Tan LK, Wang M, et al. Growth Outcomes After 48 Weeks of Dolutegravir in Children and Adolescents With HIV-1 in IMPAACT P1093 and IMPAACT 2019. Journal of the Pediatric Infectious Diseases Society. 2026. doi:10.1093/jpids/piag088
BibTeX
@article{McKenna2026,
author = {McKenna, Michael and Lulic, Zrinka and Buchanan, Ann M and Brothers, Cynthia and Tan, Lionel K and Wang, Marcia and Brummel, Sean and Ziemba, Lauren and Ruel, Theodore and Flynn, Patricia M and Rabie, Helena and Wiznia, Andrew},
title = {Growth Outcomes After 48 Weeks of Dolutegravir in Children and Adolescents With HIV-1 in IMPAACT P1093 and IMPAACT 2019},
journal = {Journal of the Pediatric Infectious Diseases Society},
year = {2026},
doi = {10.1093/jpids/piag088}
}
EUVIMED